Larvol Delta - IDEAYA-Biosciences-and-Servier-Announce-First-Patient-Dosed-in-OptimUM11-Global-Phase-3-Registrational-Trial-of-Darovasertib-and-Crizotinib-as-Adjuvant-Therapy-for-Subjects-with-Uveal-Melanoma

darovasertib (IDE196) - Ideaya Biosci

https://www.prnewswire.com/news-releases/ideaya-biosciences-and-servier-announce-first-patient-dosed-in-optimum-11-global-phase-3-registrational-trial-of-darovasertib-and-crizotinib-as-adjuvant-therapy-for-subjects-with-uveal-melanoma-302872886.html

Sep 9, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next